Scarica l'app Stockscreener
167.93
0.53%
-0.90
Dopo l'orario di chiusura:
162.00
-5.93
-3.53%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$168.83
Aprire:
$168.83
Volume 24 ore:
1.76M
Relative Volume:
1.03
Capitalizzazione di mercato:
$24.62B
Reddito:
$9.61B
Utile/perdita netta:
$1.53B
Rapporto P/E:
16.07
EPS:
10.453
Flusso di cassa netto:
$1.85B
1 W Prestazione:
+3.99%
1M Prestazione:
+17.43%
6M Prestazione:
+29.74%
1 anno Prestazione:
+8.04%
Intervallo 1D:
$165.79
$168.90
Intervallo di 1 settimana:
$161.20
$170.78
Portata 52W:
$110.03
$170.78
Biogen Inc Stock (BIIB) Company Profile
Nome
Biogen Inc
Settore
Industria
Telefono
(781) 464-2000
Indirizzo
225 BINNEY STREET, CAMBRIDGE, MA
Confronta BIIB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
167.93 | 24.77B | 9.61B | 1.53B | 1.85B | 10.45 |
|
LLY
Lilly Eli Co
|
1,049.60 | 921.91B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
202.51 | 481.86B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
232.91 | 413.34B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
127.31 | 245.62B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
95.05 | 239.34B | 63.90B | 19.05B | 13.05B | 7.5596 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-06 | Aggiornamento | Stifel | Hold → Buy |
| 2025-09-25 | Iniziato | Jefferies | Buy |
| 2025-07-21 | Ripresa | Truist | Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-04-04 | Downgrade | Argus | Buy → Hold |
| 2025-02-11 | Iniziato | Bernstein | Mkt Perform |
| 2025-01-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Downgrade | Stifel | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-09 | Downgrade | Jefferies | Buy → Hold |
| 2024-11-18 | Downgrade | Needham | Buy → Hold |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-31 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-14 | Reiterato | Needham | Buy |
| 2024-02-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2023-12-20 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-24 | Reiterato | UBS | Buy |
| 2023-05-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-04-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-10-13 | Aggiornamento | Stifel | Hold → Buy |
| 2022-10-07 | Aggiornamento | Argus | Hold → Buy |
| 2022-09-28 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-28 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Downgrade | Stifel | Buy → Hold |
| 2022-03-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Reiterato | Barclays | Equal Weight |
| 2022-02-04 | Reiterato | BofA Securities | Neutral |
| 2022-02-04 | Reiterato | Cowen | Outperform |
| 2022-02-04 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-04 | Reiterato | Needham | Buy |
| 2022-02-04 | Reiterato | Oppenheimer | Outperform |
| 2022-02-04 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Reiterato | Robert W. Baird | Neutral |
| 2022-02-04 | Reiterato | Wedbush | Neutral |
| 2022-02-04 | Reiterato | Wells Fargo | Equal Weight |
| 2022-02-04 | Reiterato | Wolfe Research | Peer Perform |
| 2022-01-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-01-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Ripresa | Raymond James | Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-06-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Reiterato | Truist | Buy |
| 2021-06-11 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-08 | Aggiornamento | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Reiterato | Barclays | Equal Weight |
| 2021-06-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-08 | Reiterato | Jefferies | Buy |
| 2021-06-08 | Reiterato | Morgan Stanley | Overweight |
| 2021-06-08 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Reiterato | Stifel | Buy |
| 2021-06-08 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-06-07 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Downgrade | DZ Bank | Buy → Hold |
| 2021-01-29 | Aggiornamento | Stifel | Hold → Buy |
| 2020-11-10 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-11-09 | Downgrade | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-11-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-04 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-11-04 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-07-27 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Downgrade | Citigroup | Neutral → Sell |
| 2020-04-23 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-27 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Downgrade | Robert W. Baird | Neutral → Underperform |
Mostra tutto
Biogen Inc Borsa (BIIB) Ultime notizie
Why Biogen Inc. stock is considered a top pick2025 Earnings Surprises & AI Powered Buy and Sell Recommendations - newser.com
Is Biogen Inc. (IDP) stock a buy before earnings results2025 EndofYear Setup & Growth Focused Stock Reports - newser.com
Why Biogen Inc. (IDP) stock benefits from AI revolutionWeekly Trade Recap & AI Powered Market Entry Ideas - newser.com
Biogen to Participate in Upcoming Investor Conferences - Biogen
How analysts rate Biogen Inc. stock todayWeekly Risk Report & Consistent Profit Alerts - newser.com
Does Biogen’s (BIIB) Rare Disease Pipeline Gain Momentum with New Dravet Study Data? - simplywall.st
Biogen’s SWOT analysis: mixed outlook as Alzheimer’s drug gains traction amid stock valuation concerns - Investing.com Nigeria
Biogen Options Trading: A Deep Dive into Market Sentiment - Benzinga
Biogen, Stoke Release Final BUTTERFLY Study Data - Nasdaq
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom - TradingView
Biogen Stock: Is Wall Street Bullish or Bearish? - Yahoo Finance
Biogen (BIIB) and Stoke Release Results from Dravet Syndrome Stu - GuruFocus
Biogen (BIIB) Reveals Key Findings from Dravet Syndrome Study - GuruFocus
Biogen Says EU Committee Recommends Approval of High Dose Nusinersen Regimen - MarketScreener
Biogen Completes Acquisition of Alcyone Therapeutics - FinSMEs
BIIBBiogen Inc Latest Stock News & Market Updates - Stock Titan
European regulator backs high-dose nusinersen for spinal muscular atrophy By Investing.com - Investing.com Australia
European regulator backs high-dose nusinersen for spinal muscular atrophy - Investing.com
Biogen (BIIB) Advances High Dose Spinal Muscular Atrophy Treatme - GuruFocus
Biogen acquires Alcyone to boost CNS drug delivery - Yahoo Finance
High dose regimen of Nusinersen receives positive CHMP opinion for the treatment of spinal muscular atrophy - MarketScreener
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy - Biogen
Why Biogen Inc. (IDP) stock stays on top picksWeekly Trend Recap & AI Driven Price Predictions - newser.com
Chart based exit strategy for Biogen Inc.Portfolio Update Summary & AI Based Buy and Sell Signals - newser.com
Key metrics from Biogen Inc.’s quarterly dataRisk Management & Daily Risk Controlled Trade Plans - newser.com
Will Biogen Inc. (IDP) stock benefit from commodity supercycle2025 Key Lessons & AI Driven Stock Price Forecasts - newser.com
STATE STREET CORP Reduces Stake in Biogen Inc: A Detailed Analys - GuruFocus
Analyzing Biogen Inc. with multi timeframe chartsJuly 2025 Retail & Verified Momentum Watchlists - newser.com
Biogen completes acquisition of Alcyone Therapeutics By Investing.com - Investing.com India
Fund Update: 282,084 BIOGEN (BIIB) shares added to Zurcher Kantonalbank (Zurich Cantonalbank) portfolio - Quiver Quantitative
Biogen completes acquisition of Alcyone Therapeutics - MarketScreener
How Biogen Inc. (IDP) stock behaves in tightening cyclesWeekly Profit Analysis & Fast Entry and Exit Trade Plans - newser.com
Discipline and Rules-Based Execution in BIIB Response - news.stocktradersdaily.com
Biogen stock hits 52-week high at 167.87 USD By Investing.com - Investing.com Canada
Biogen stock hits 52-week high at 167.87 USD - Investing.com India
How to escape a deep drawdown in Biogen Inc.Trade Exit Summary & Stepwise Trade Signal Implementation - newser.com
Biogen (BIIB) Gains UK Approval for LEQEMBI Maintenance Dosing - GuruFocus
'LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom - The Manila Times
Eisai and Biogen's LEQEMBI® Receives Approval for Once Every Four Weeks IV Maintenance Dosing in the UK - Quiver Quantitative
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom - Biogen
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom - GlobeNewswire Inc.
Biogen at TD Cowen Summit: Strategic Focus on I&I and Kidney Innovation - Investing.com
Biogen (BIIB) Valuation in Focus Following Q3 2025 Results and Key Medical Conference Updates - simplywall.st
Biogen Inc: Time to Ride the Surge? - timothysykes.com
What the Options Market Tells Us About Biogen - Benzinga
Biogen Inc. Stock Outperforms Competitors On Strong Trading Day - 富途牛牛
Shine a Light on Healthcare ETFs Amid National Alzheimer's Awareness Month - Yahoo Finance
Biogen’s Alzheimer’s Bet: Can the EVOKE Trial Redefine the Future of Neurology? - Smartkarma
Institutional scanner results for Biogen Inc.Earnings Risk Report & AI Driven Stock Reports - newser.com
Biogen Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains - 富途牛牛
Biogen Inc Azioni (BIIB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Biogen Inc Azioni (BIIB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Godbout Sean | Chief Accounting Officer |
Oct 02 '25 |
Option Exercise |
0.00 |
26 |
0 |
503 |
| Singhal Priya | Head of Development |
Aug 29 '25 |
Option Exercise |
0.00 |
1,669 |
0 |
7,096 |
| Singhal Priya | Head of Development |
Sep 02 '25 |
Sale |
133.55 |
517 |
69,045 |
5,772 |
2.19%
0.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):